Nippon Chemiphar Co., Ltd. (4539.T)
JPY 1440.0
(-0.07%)
JPY 1440.0
(-0.07%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.4 Billion JPY | -42.59% |
| 2022 | 1.26 Billion JPY | -38.31% |
| 2021 | 2.41 Billion JPY | 29.89% |
| 2020 | 1.95 Billion JPY | 23.27% |
| 2019 | 1.63 Billion JPY | -43.0% |
| 2018 | 2.8 Billion JPY | -1.19% |
| 2017 | 3.04 Billion JPY | -26.24% |
| 2016 | 3.94 Billion JPY | -4.63% |
| 2015 | 4.29 Billion JPY | -9.1% |
| 2014 | 8.16 Billion JPY | 7.12% |
| 2013 | 4.26 Billion JPY | -10.05% |
| 2012 | 4.79 Billion JPY | 25.8% |
| 2011 | 3.82 Billion JPY | 32.04% |
| 2010 | 2.55 Billion JPY | 95.56% |
| 2009 | 1.48 Billion JPY | 40.6% |
| 2008 | 1.21 Billion JPY | -23.56% |
| 2007 | 1.31 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 118 Million JPY | -78.47% |
| 2024 Q1 | 367.75 Million JPY | 495.65% |
| 2023 FY | - JPY | -42.59% |
| 2023 Q3 | 612 Million JPY | 1071.43% |
| 2023 Q2 | -63 Million JPY | -144.37% |
| 2023 Q1 | 142 Million JPY | 130.47% |
| 2023 Q4 | -64 Million JPY | -110.46% |
| 2022 FY | - JPY | -38.31% |
| 2022 Q1 | 544 Million JPY | 613.21% |
| 2022 Q4 | -466 Million JPY | -179.04% |
| 2022 Q2 | 270 Million JPY | -50.37% |
| 2022 Q3 | -167 Million JPY | -161.85% |
| 2021 Q4 | -106 Million JPY | -110.06% |
| 2021 Q1 | 44 Million JPY | -84.83% |
| 2021 Q2 | 274 Million JPY | 522.73% |
| 2021 Q3 | 1.05 Billion JPY | 284.67% |
| 2021 FY | - JPY | 29.89% |
| 2020 Q3 | 597 Million JPY | 514.58% |
| 2020 Q4 | 290 Million JPY | -51.42% |
| 2020 FY | - JPY | 23.27% |
| 2020 Q1 | -38 Million JPY | 81.99% |
| 2020 Q2 | -144 Million JPY | -278.95% |
| 2019 Q1 | 626 Million JPY | 309.15% |
| 2019 FY | - JPY | -43.0% |
| 2019 Q2 | -51 Million JPY | -108.15% |
| 2019 Q3 | 508 Million JPY | 1096.08% |
| 2019 Q4 | -211 Million JPY | -141.54% |
| 2018 Q2 | 361 Million JPY | -28.23% |
| 2018 Q1 | 503 Million JPY | 629.47% |
| 2018 Q4 | 153 Million JPY | -73.8% |
| 2018 FY | - JPY | -1.19% |
| 2018 Q3 | 584 Million JPY | 61.77% |
| 2017 Q2 | 508 Million JPY | -18.46% |
| 2017 Q1 | 623 Million JPY | 23.86% |
| 2017 FY | - JPY | -26.24% |
| 2017 Q4 | -95 Million JPY | -110.87% |
| 2017 Q3 | 874 Million JPY | 72.05% |
| 2016 Q2 | 533 Million JPY | -22.3% |
| 2016 Q4 | 503 Million JPY | -60.17% |
| 2016 FY | - JPY | -4.63% |
| 2016 Q3 | 1.26 Billion JPY | 136.96% |
| 2016 Q1 | 686 Million JPY | 20.99% |
| 2015 Q4 | 567 Million JPY | -50.39% |
| 2015 FY | - JPY | -9.1% |
| 2015 Q3 | 1.14 Billion JPY | 51.19% |
| 2015 Q2 | 756 Million JPY | 19.81% |
| 2015 Q1 | 631 Million JPY | 46.74% |
| 2014 Q3 | 1.18 Billion JPY | 66.85% |
| 2014 Q4 | 430 Million JPY | -63.65% |
| 2014 FY | - JPY | 7.12% |
| 2014 Q1 | 1.05 Billion JPY | 126.45% |
| 2014 Q2 | 709 Million JPY | -32.67% |
| 2013 Q3 | 1.22 Billion JPY | 52.17% |
| 2013 Q4 | 465 Million JPY | -62.04% |
| 2013 FY | - JPY | -10.05% |
| 2013 Q1 | 882 Million JPY | 100.45% |
| 2013 Q2 | 805 Million JPY | -8.73% |
| 2012 Q3 | 1.11 Billion JPY | -3.05% |
| 2012 Q1 | 1.19 Billion JPY | 204.07% |
| 2012 Q4 | 440 Million JPY | -60.4% |
| 2012 FY | - JPY | 25.8% |
| 2012 Q2 | 1.14 Billion JPY | -4.1% |
| 2011 Q2 | 568 Million JPY | -25.46% |
| 2011 Q3 | 1.25 Billion JPY | 121.13% |
| 2011 Q4 | 393 Million JPY | -68.71% |
| 2011 FY | - JPY | 32.04% |
| 2011 Q1 | 762 Million JPY | 7.63% |
| 2010 FY | - JPY | 95.56% |
| 2010 Q3 | 877 Million JPY | 14.04% |
| 2010 Q1 | 598 Million JPY | 59.89% |
| 2010 Q4 | 708 Million JPY | -19.27% |
| 2010 Q2 | 769 Million JPY | 28.6% |
| 2009 Q2 | 303 Million JPY | 3.77% |
| 2009 Q1 | 292 Million JPY | -20.22% |
| 2009 FY | - JPY | 40.6% |
| 2009 Q4 | 374 Million JPY | -30.61% |
| 2009 Q3 | 539 Million JPY | 77.89% |
| 2008 Q2 | 82 Million JPY | 0.0% |
| 2008 Q4 | 366 Million JPY | 2.23% |
| 2008 FY | - JPY | -23.56% |
| 2008 Q3 | 358 Million JPY | 336.59% |
| 2007 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | 76.698% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 99.84% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 100.499% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 99.249% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | -145.721% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 96.134% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 88.563% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 98.639% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | -8.507% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 92.35% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | 84.364% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | 61.771% |
| Tsumura & Co. | 30.77 Billion JPY | 95.441% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 92.505% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | 73.383% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 96.052% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | 79.613% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 91.993% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | 86.373% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 137.413% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | 81.425% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | 296.499% |
| MedRx Co., Ltd | -884.51 Million JPY | 258.618% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | 74.658% |
| Solasia Pharma K.K. | -635 Million JPY | 320.945% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 159.1% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | 84.688% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 96.195% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | 360.641% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 94.571% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | 72.499% |